Get the Stockscreener App
12.94
4.19%
0.52
After Hours:
12.86
-0.08
-0.62%
Theravance Biopharma Inc stock is traded at $12.94, with a volume of 874.50K.
It is up +4.19% in the last 24 hours and up +12.82% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$12.42
Open:
$12.42
24h Volume:
874.50K
Relative Volume:
3.12
Market Cap:
$647.02M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-14.07
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+15.43%
1M Performance:
+12.82%
6M Performance:
+34.65%
1Y Performance:
+58.19%
1-Day Range:
$12.27
$13.14
1-Week Range:
$11.20
$13.14
52-Week Range:
$7.88
$13.14
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
12.94 | 625.97M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - uk.finance.yahoo.com
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com UK
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
What institutional flow reveals about Theravance Biopharma Inc.Trade Safety Matrix for Conservative Traders - Newser
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Bio: Q2 Earnings Snapshot - San Francisco Chronicle
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Is Theravance Biopharma Inc. still worth holding after the dipFree Smart Money Tracking Signal Generator - Newser
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedTrend Confirmation Scanner with Entry Focus - Newser
Signal strength of Theravance Biopharma Inc. stock in tech scannersRisk Aware Trading Ideas with Alert Levels - Newser
Real time pattern detection on Theravance Biopharma Inc. stockIntraday Signal Forecast for Fast Traders - Newser
Price momentum metrics for Theravance Biopharma Inc. explainedFree News Based Entry Opportunity Alerts - Newser
Tools to monitor Theravance Biopharma Inc. recovery probabilitySwing Watchlist With Tight Stop Placement - Newser
Using data models to predict Theravance Biopharma Inc. stock movementSmart Stock Forecast Using AI Algorithms - Newser
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateTechnical Entry Plan with Risk Minimization - Newser
Theravance Biopharma Inc expected to post earnings of 67 cents a shareEarnings Preview - TradingView
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFree Conservative Entry for High Return Setup - Newser
What makes Theravance Biopharma Inc. stock price move sharplyHigh Conviction Screener with Trend Matching - Newser
How Theravance Biopharma Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Technical Charts Suggest Momentum Shift in Theravance Biopharma Inc.Chart Driven Price Action Analysis - beatles.ru
What’s the recovery path for long term holders of Theravance Biopharma Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
What is the dividend policy of Theravance Biopharma Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Theravance Biopharma Inc.Maximize gains with timely market signals - Jammu Links News
What are the technical indicators suggesting about Theravance Biopharma Inc.High-velocity gains - Jammu Links News
How volatile is Theravance Biopharma Inc. stock compared to the marketBreakthrough profits - Jammu Links News
What analysts say about Theravance Biopharma Inc. stockSuperior returns - Jammu Links News
Should I hold or sell Theravance Biopharma Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What is Theravance Biopharma Inc. company’s growth strategyMaximize your gains with professional insights - Jammu Links News
What drives Theravance Biopharma Inc. stock priceAchieve rapid returns with smart investment plans - Jammu Links News
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):